Serplulimab for Patients With Non-small Cell Lung Cancer (NSCLC) With TPS ≥ 50%: a Prospective, Single-center, Single-arm Phase 2 Study.

Clinical trial NCT06195683 · UNKNOWN

Trial details

NCT number: NCT06195683
Sponsor: Zhejiang Cancer Hospital
Status: UNKNOWN
Phase: Phase 2
Study type: INTERVENTIONAL

Non-small Cell Lung Cancer PDL1 Gene Mutation

Start date: 2023-12-01
Primary completion: 2024-12-31
Enrollment: 23

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.